EMEA-002795-PIP01-20
Key facts
| Active substance |
Respiratory syncytial virus stabilised prefusion f subunit vaccine (RSVpreF)
|
| Therapeutic area |
Vaccines
|
| Decision number |
P/0202/2021
|
| PIP number |
EMEA-002795-PIP01-20
|
| Pharmaceutical form(s) |
Powder and solvent for solution for injection
|
| Condition(s) / indication(s) |
Prevention of lower respiratory tract disease caused by respiratory syncytial virus via maternal immunisation
|
| Route(s) of administration |
Intramuscular use
|
| Contact for public enquiries |
Pfizer Europe MA EEIG
E-mail: pip_enquiries@pfizer.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|